At Svar, we work to provide the right answers at the right time, from drug discovery to diagnosis and beyond. To meet this challenge, we aim to deliver new and innovative solutions, and value the importance of partnerships and collaborations in these efforts.
We strongly believe that the sharing of knowledge, skills and networks is not only a key driver for innovation, but the key to pioneering new solutions and finding new partnering opportunities.
Svar has a strong track record in pioneering new solutions within clinical diagnostics and drug discovery, such as our anti-CCP2 and CCPoint assays for early diagnosis of RA, our functional assays for all three pathways of complement activation, and iLite®, our cell-based reporter gene assays with features that are new and unique on the market.
In order to lead the market and continue successfully pioneering new solutions, we must team up and establish strong partnerships with collaborators, big and small. As a result, we have longstanding partnerships with top diagnostic platform providers, allowing us to serve 50% of the global autoimmunity market. Within the drug discovery segment, we collaborate with 15 of the 20 largest biopharma and CRO companies. Combined, this gives us a unique access and a large platform, from which we are constantly looking for new, cutting-edge solutions by partnering with up-and-coming researchers and companies.